Akums Drugs and Pharmaceuticals Limited (IN:AKUMS)
:AKUMS
Want to see IN:AKUMS full AI Analyst Report?
AKUMS Stock Chart & Stats
₹420.10
₹13.30(2.17%)
At close: 4:00 PM EST
₹420.10
₹13.30(2.17%)
Day’s Range― - ―
52-Week Range₹410.10 - ₹620.00
Previous CloseN/A
Volume56.90K
Average Volume (3M)11.50K
Market Cap
₹80.94B
Enterprise Value₹64.59B
Total Cash (Recent Filing)₹16.78B
Total Debt (Recent Filing)₹902.87M
Price to Earnings (P/E)28.0
Beta1.31
Next Earnings
Aug 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)12.42
Shares Outstanding157,393,980
10 Day Avg. Volume12,021
30 Day Avg. Volume11,497
Financial Highlights & Ratios
PEG Ratio-1.07
Price to Book (P/B)2.15
Price to Sales (P/S)1.64
P/FCF Ratio7.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)24.3
Revenue Forecast (FY)₹49.26B
Bulls Say, Bears Say
Bulls Say
Low Leverage / Stronger Balance SheetLeverage fell to ~0.03–0.05 with equity expansion, materially strengthening the capital base. This durable balance-sheet repair reduces interest burden, supports capex or strategic M&A, and increases resilience to sector cyclicality over the coming months.
Strong Operating And Free Cash Flow RecoveryMaterial cash generation (OCF ~₹12.1B, FCF ~₹9.8B) demonstrates the business can convert earnings into cash. Reliable cash flow supports reinvestment, working-capital needs and lowers reliance on external financing, improving strategic optionality over 2–6 months.
CDMO Model With Revenue ExpansionAs an end-to-end CDMO serving multiple dosage forms and export markets, Akums benefits from structural outsourcing trends. Steady revenue growth to ₹43.6B indicates client traction and diversified manufacturing demand that supports durable top-line stability.
Bears Say
Sharp Margin Contraction In FY26A meaningful drop in gross and net margins in FY26 suggests cost pressures, adverse product mix, or pricing weakness. If sustained, margin compression will erode returns and limit capacity to fund growth or absorb shocks across the next several quarters.
Volatile Cash Flow HistoryDespite recent improvement, FCF declined in FY26 versus FY25 and was negative in FY22–FY23, indicating inconsistent conversion. This volatility undermines predictability for capex, debt servicing and shareholder returns, raising execution risk for medium-term plans.
Negative EPS Growth Over PeriodReported EPS growth is negative (~-25%), reflecting uneven profitability and sensitivity to margin or volume swings. Continued EPS volatility weakens forecasting reliability and may constrain management's ability to demonstrate a sustained earnings recovery.
Akums Drugs and Pharmaceuticals Limited News
AKUMS FAQ
What was Akums Drugs and Pharmaceuticals Limited’s price range in the past 12 months?
Akums Drugs and Pharmaceuticals Limited lowest stock price was ₹410.10 and its highest was ₹620.00 in the past 12 months.
What is Akums Drugs and Pharmaceuticals Limited’s market cap?
Akums Drugs and Pharmaceuticals Limited’s market cap is ₹80.94B.
When is Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date?
Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date is Aug 24, 2026 which is in 94 days.
How were Akums Drugs and Pharmaceuticals Limited’s earnings last quarter?
Akums Drugs and Pharmaceuticals Limited released its earnings results on May 14, 2026. The company reported ₹5.53 earnings per share for the quarter, beating the consensus estimate of N/A by ₹5.53.
Is Akums Drugs and Pharmaceuticals Limited overvalued?
According to Wall Street analysts Akums Drugs and Pharmaceuticals Limited’s price is currently Overvalued.
Does Akums Drugs and Pharmaceuticals Limited pay dividends?
Akums Drugs and Pharmaceuticals Limited does not currently pay dividends.
What is Akums Drugs and Pharmaceuticals Limited’s EPS estimate?
Akums Drugs and Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Akums Drugs and Pharmaceuticals Limited have?
Akums Drugs and Pharmaceuticals Limited has 157,393,980 shares outstanding.
What happened to Akums Drugs and Pharmaceuticals Limited’s price movement after its last earnings report?
Akums Drugs and Pharmaceuticals Limited reported an EPS of ₹5.53 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.69%.
Which hedge fund is a major shareholder of Akums Drugs and Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:AKUMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Akums Drugs and Pharmaceuticals Limited
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, herbals, toiletries, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offers branded formulations on various dosage forms, including tablets, capsules, injectables, opthalmics, and soft gelatin capsules for therapeutic areas, such as gynaecology, cardiology, orthopaedics, pediatrics, and dermatology, as well as anti-infectives, pain management and gastroenterology. In addition, the company operates as pharmaceutical contract development and manufacturing company. The company was incorporated in 2004 and is based in Delhi, India.
Technical Analysis
Bafna Pharmaceuticals Limited
―
Bal Pharma Limited
―
Indraprastha Medical Corporation Limited
―
Kopran Limited
―
Wanbury Limited
―